Novo Nordisk entered a collaboration with Anthropic to test Anthropic’s Claude Science across Novo’s R&D workflows, aiming to speed development and strengthen software engineering. Novo said it did not disclose financial details, but characterized the project as an initial effort focused on specific research and development tasks where it expects the greatest impact. Novo CEO Mike Doustdar said joining forces with Anthropic would “supercharge” the company’s R&D organization, with an emphasis on applying frontier models to scientific reasoning and agentic software engineering to scale internal AI use. The announcement also signals how major pharma is operationalizing AI collaborations beyond pilots, seeking to embed AI tools into routine discovery and development processes while acknowledging error and guardrail challenges. For biotech teams, the deal demonstrates increasing corporate demand for AI systems that can integrate with enterprise workflows and improve productivity, not only generate outputs.